$ARAT
Arax Holdings Corp

2023 Form 10-K Financial Statement

#000175392624000855 Filed on April 26, 2024

View on sec.gov

Income Statement

Concept 2023 2022
Revenue $909.2K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $90.00K $148.6K
YoY Change -39.44% 12.76%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $901.6K $148.6K
YoY Change 506.7% 12.77%
Operating Profit $7.536K -$148.6K
YoY Change -105.07% 12.77%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$830.00
YoY Change
Pretax Income -$18.54M -$148.6K
YoY Change 12377.76% 12.77%
Income Tax
% Of Pretax Income
Net Earnings -$18.54M -$148.6K
YoY Change 12377.76% 12.77%
Net Earnings / Revenue -2039.6%
Basic Earnings Per Share -$0.15 -$0.01
Diluted Earnings Per Share -$0.22 -$0.01
COMMON SHARES
Basic Shares Outstanding 82.81M shares 10.34M shares
Diluted Shares Outstanding 10.34M shares

Balance Sheet

Concept 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.449M
YoY Change
Cash & Equivalents $1.449M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $227.0K
Other Receivables $0.00
Total Short-Term Assets $1.676M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.510K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $437.4K
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $5.472M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.676M
Total Long-Term Assets $5.472M
Total Assets $7.148M $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $100.4K $116.9K
YoY Change -14.11% 725.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $258.1K $174.6K
YoY Change 47.82% 571.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $258.1K $174.6K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $258.1K $174.6K
YoY Change 47.82% 571.4%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.890M -$174.6K
YoY Change
Total Liabilities & Shareholders Equity $7.148M $0.00
YoY Change

Cashflow Statement

Concept 2023 2022
OPERATING ACTIVITIES
Net Income -$18.54M -$148.6K
YoY Change 12377.76% 12.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$18.86M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $5.033M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$269.6K $0.00
YoY Change
Cash From Investing Activities -$5.303M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $115.8K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $25.61M
YoY Change
NET CHANGE
Cash From Operating Activities -$18.86M
Cash From Investing Activities -$5.303M
Cash From Financing Activities $25.61M
Net Change In Cash $1.449M $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$18.86M
Capital Expenditures $5.033M
Free Cash Flow -$23.89M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Assets
Assets
usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
usd
CY2022 us-gaap Revenues
Revenues
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2022 arat Issuance Of Preferred Stock And Forgivenes Of Debt Treated As Capital Contribution
IssuanceOfPreferredStockAndForgivenesOfDebtTreatedAsCapitalContribution
usd
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
usd
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2022 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
usd
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
CY2022 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
CY2023 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19422584 usd
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
0 usd
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
0 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Public Float
EntityPublicFloat
28490187 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
127588506 shares
CY2023 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2023 dei Auditor Firm
AuditorFirmId
5041
CY2023 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1448769 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
226951 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1675720 usd
CY2023Q4 us-gaap Land And Land Improvements
LandAndLandImprovements
1510 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
5033332 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
437373 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
100000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
258134 usd
CY2023Q4 us-gaap Liabilities
Liabilities
258134 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
10000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126160534 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10335294 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10335294 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
126160 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10335 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26176224 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
684046 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19422584 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-879006 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6889800 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-174625 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7147934 usd
CY2023 us-gaap Revenues
Revenues
909176 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
811639 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73613 usd
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90000 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
75000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
901639 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
148613 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
7536 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-148613 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-830 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18543578 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-148613 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-18543578 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-148613 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82811424 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10335294 shares
CY2021 arat Issuance Of Preferred Stock And Forgivenes Of Debt Treated As Capital Contribution
IssuanceOfPreferredStockAndForgivenesOfDebtTreatedAsCapitalContribution
100000 usd
CY2021 arat Forgiveness Of Debt Treated As A Capital Contribution
ForgivenessOfDebtTreatedAsACapitalContribution
5775 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-131787 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-26012 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-26012 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-148613 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-174625 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-174625 usd
CY2023 arat Issuance Of Preferred Stock And Forgivenes Of Debt Treated As Capital Contribution
IssuanceOfPreferredStockAndForgivenesOfDebtTreatedAsCapitalContribution
25608003 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-18543578 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6889800 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18543578 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-148613 usd
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
226951 usd
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-45894 usd
CY2023 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-69293 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16491 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
102719 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18856313 usd
CY2023 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
5033332 usd
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
269589 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5302921 usd
CY2023 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
24052178 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
115825 usd
CY2023 arat Common Stock To Be Issued
CommonStockToBeIssued
1440000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25608003 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1448769 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1448769 usd
CY2023Q4 arat Working Capital Deficit
WorkingCapitalDeficit
25371682 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zgnecuMj2CW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zYhoUa6bO1Eg">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000000 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023 arat Common Stock Issued For Loan And Compensation Expenses
CommonStockIssuedForLoanAndCompensationExpenses
100000 usd
CY2023 us-gaap Repayments Of Debt
RepaymentsOfDebt
16166 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
83834 usd
CY2021Q2 us-gaap Increase Decrease In Notes Payable Related Parties Current
IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
5775 usd
CY2023Q4 arat Advances Related Party Transaction Due From To Related Party
AdvancesRelatedPartyTransactionDueFromToRelatedParty
57756 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
6413760 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 pure
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-184591 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-153383 usd
CY2023 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-184591 usd
CY2022 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-153383 usd
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
184591 usd

Files In Submission

Name View Source Status
0001753926-24-000855-index-headers.html Edgar Link pending
0001753926-24-000855-index.html Edgar Link pending
0001753926-24-000855.txt Edgar Link pending
0001753926-24-000855-xbrl.zip Edgar Link pending
arat-20231031.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g083947_10k.htm Edgar Link pending
g083947_ex31-1.htm Edgar Link pending
g083947_ex31-2.htm Edgar Link pending
g083947_ex32-1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
arat-20231031_cal.xml Edgar Link unprocessable
arat-20231031_def.xml Edgar Link unprocessable
arat-20231031_lab.xml Edgar Link unprocessable
arat-20231031_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
g083947_10k_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending